(Q37082148)

18 August 2017

1 reference

title

Treatment of dementia associated with Parkinson's disease (English)

1 reference

18 August 2017

0 references

1 reference

M Emre

1

1 reference

18 August 2017

publication date

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

published in

1 reference

18 August 2017

volume

13 Suppl 3

1 reference

18 August 2017

page(s)

S457-61

1 reference

A systematic review of prevalence studies of dementia in Parkinson's disease

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

What causes mental dysfunction in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Basal forebrain neurons in the dementia of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Cholinergic dysfunction in diseases with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

The use of memantine in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Clozapine and risperidone treatment of psychosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Atypical antipsychotics in Parkinson-sensitive populations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Antidepressant studies in Parkinson's disease: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970049-X

7 January 2021

10.1016/S1353-8020(08)70049-X

Identifiers

DOI

1 reference

18 August 2017

1 reference